Hypofractionated Versus Conventional Postmastectomy Irradiation for Breast Cancer: Comparison of Acute Skin Toxicity

Overview

Journal Breast Cancer (Dove Med Press)

Publisher Dove Medical Press

Date 2024 Aug 5

PMID 39099624

Authors

Zhiyuan Wu

Lili Hou

Cheng Li

Xiaohua Li

Ying Li

Affiliations

Soon will be listed here.

Abstract

Purpose: Breast cancer is the leading cause of cancer mortality among women. Radiotherapy can reduce recurrence and prolong survival of patients accepting breast-conserving surgery (BCS). This study aims to compare acute skin reactions in patients receiving hypofractionated versus conventional radiotherapy at a single institution and to summarize the relevant influencing factors.

Methods: This study analyzed 152 patients who underwent either hypofractionated or conventional whole-breast irradiation (WBI) after BCS. Acute skin toxicity was assessed according to the Radiation Therapy Oncology Group (RTOG) criteria. Predictive factors for acute skin toxicity were identified using multivariate analysis and visualized using a forest spot.

Results: Grade 0 reactions occurred in 75.34% vs 70.89%, grade 1 in 16.44% vs 15.19%, grade 2 in 8.22% vs 12.66%, and grade 3 in 0% vs 1.27% of patients receiving hypofractionated and conventional WBI, respectively. There was no statistically significant difference in acute skin reaction in patients treated with hypofractionated radiation compared with conventional radiation ( = 0.62). Multivariate analysis revealed that metastatic lymph nodes ( = 0.021), whole-breast planning target volume (PTV-WB) ( 0.001), and tumor bed planning target volume (PTV-TB) ( = 0.002) were significantly correlated with higher rates of acute skin toxicity.

Conclusion: Hypofractionated WBI demonstrated similar acute skin adverse reactions compared to conventional WBI. These findings indicate that hypofractionated radiotherapy offers comparable tolerance, equivalent curative effect, convenience, and economic benefits, supporting its clinical promotion.

References

Bourgier C, Cowen D, Castan F, Lemanski C, Gourgou S, Rivera S . Quality assurance program and early toxicities in the phase III BONBIS randomized trial evaluating the role of a localized radiation boost in ductal carcinoma in situ. Radiother Oncol. 2021; 164:57-65. DOI: 10.1016/j.radonc.2021.09.014. View

Van Limbergen E, van der Schueren E, Van Tongelen K . Cosmetic evaluation of breast conserving treatment for mammary cancer. 1. Proposal of a quantitative scoring system. Radiother Oncol. 1989; 16(3):159-67. DOI: 10.1016/0167-8140(89)90016-9. View

Owen J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J . Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol. 2006; 7(6):467-71. DOI: 10.1016/S1470-2045(06)70699-4. View

Tortorelli G, Di Murro L, Barbarino R, Cicchetti S, di Cristino D, Falco M . Standard or hypofractionated radiotherapy in the postoperative treatment of breast cancer: a retrospective analysis of acute skin toxicity and dose inhomogeneities. BMC Cancer. 2013; 13:230. PMC: 3660202. DOI: 10.1186/1471-2407-13-230. View

Bentzen S, Agrawal R, Aird E, Barrett J, Barrett-Lee P, Bliss J . The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008; 9(4):331-41. PMC: 2323709. DOI: 10.1016/S1470-2045(08)70077-9. View

Offersen B, Alsner J, Nielsen H, Jakobsen E, Nielsen M, Krause M . Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial. J Clin Oncol. 2020; 38(31):3615-3625. DOI: 10.1200/JCO.20.01363. View

Faverly D, Hendriks J, Holland R . Breast carcinomas of limited extent: frequency, radiologic-pathologic characteristics, and surgical margin requirements. Cancer. 2001; 91(4):647-59. DOI: 10.1002/1097-0142(20010215)91:4<647::aid-cncr1053>3.0.co;2-z. View

Parekh A, Dholakia A, Zabranksy D, Asrari F, Camp M, Habibi M . Predictors of radiation-induced acute skin toxicity in breast cancer at a single institution: Role of fractionation and treatment volume. Adv Radiat Oncol. 2018; 3(1):8-15. PMC: 5856985. DOI: 10.1016/j.adro.2017.10.007. View

Haviland J, Owen J, Dewar J, Agrawal R, Barrett J, Barrett-Lee P . The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013; 14(11):1086-1094. DOI: 10.1016/S1470-2045(13)70386-3. View

10.

van den Brandt P, Spiegelman D, Yaun S, Adami H, Beeson L, Folsom A . Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000; 152(6):514-27. DOI: 10.1093/aje/152.6.514. View

11.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

12.

Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J . Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2014; 16(1):47-56. DOI: 10.1016/S1470-2045(14)71156-8. View

13.

Montero A, Ciervide R, Canadillas C, Alvarez B, Garcia-Aranda M, Alonso R . Acute skin toxicity of ultra-hypofractionated whole breast radiotherapy with simultaneous integrated boost for early breast cancer. Clin Transl Radiat Oncol. 2023; 41:100651. PMC: 10300060. DOI: 10.1016/j.ctro.2023.100651. View

14.

Khan M, Gupta M, Seam R . Analysis of cardiac adverse events following postmastectomy hypofractionated radiotherapy. Chin Clin Oncol. 2015; 3(4):47. DOI: 10.3978/j.issn.2304-3865.2014.06.06. View

15.

Lei S, Zheng R, Zhang S, Chen R, Wang S, Sun K . Breast cancer incidence and mortality in women in China: temporal trends and projections to 2030. Cancer Biol Med. 2021; . PMC: 8330522. DOI: 10.20892/j.issn.2095-3941.2020.0523. View

16.

Krug D, Vonthein R, Schreiber A, Boicev A, Zimmer J, Laubach R . Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trial. Strahlenther Onkol. 2020; 197(9):802-811. PMC: 8397631. DOI: 10.1007/s00066-020-01730-9. View

17.

Brunt A, Haviland J, Sydenham M, Agrawal R, Algurafi H, Alhasso A . Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer. J Clin Oncol. 2020; 38(28):3261-3272. PMC: 7526720. DOI: 10.1200/JCO.19.02750. View

18.

Fodor A, Brombin C, Mangili P, Tummineri R, Pasetti M, Zerbetto F . Toxicity of Hypofractionated Whole Breast Radiotherapy Without Boost and Timescale of Late Skin Responses in a Large Cohort of Early-Stage Breast Cancer Patients. Clin Breast Cancer. 2021; 22(4):e480-e487. DOI: 10.1016/j.clbc.2021.11.008. View

19.

DeSantis C, Ma J, Gaudet M, Newman L, Miller K, Sauer A . Breast cancer statistics, 2019. CA Cancer J Clin. 2019; 69(6):438-451. DOI: 10.3322/caac.21583. View

20.

Agrawal R, Aird E, Barrett J, Barrett-Lee P, Bentzen S, Bliss J . The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008; 371(9618):1098-107. PMC: 2277488. DOI: 10.1016/S0140-6736(08)60348-7. View